CDK2 and cancer: Our findings strengthen the notion that CDK2 is a relevant and promising target for cancer therapy (6, 13, 41) and support the current efforts by Incyclix Bio, Pfizer, Blueprint Medicines, Incyte, and Allorion Therapeutics to develop CDK2 inhibitors in the clinic.